<DOC>
	<DOCNO>NCT00694278</DOCNO>
	<brief_summary>The aim study primary outcome clinically evaluate effect laparoscopic duodenal-jejunal bypass non-obese type 2 diabetes . Secondary outcome evaluate CCK , FFA , Cholesterol Ghrelin , C-peptide , HbA1c level . Patients follow closely ensure desired result sustain long term</brief_summary>
	<brief_title>Clinical Evaluation Effect Duodenal-Jejunal Bypass Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Adults age 2065 year Clinical diagnosis type II diabetes buy follow three criterion ( American Diabetes Association ) 1 . A normal high Cpeptide level ( exclude type 1 diabetes ) ( &gt; .9ng/ml ) 2 . A random plasma glucose 200mg/dl typical symptom diabetes 3 . A fasting plasma glucose 126mg/dl one occasion BMI 2234 KG/m2 Patients oral hypoglycemic medication insulin control T2DM Inadequate control diabetes define HbA1c &gt; 7.5 No contraindication surgery General Anesthesia determine multidisciplinary surgical team Ability understand describe mechanism action rick benefit operation Patients meet follow exclusion criterion exclusion criterion exclude enrollment study Enrolled another clinical study involve investigational drug Diagnosis type 1 diabetes Pregnancy ( female patient beta HCG ) plan pregnancy within 2 year entry study unwilling use reliable contraceptive method Previous gastric esophageal surgery Immunosuppressive drug include corticosteroid Coagulopathy ( INR &gt; 1.5 platelet &lt; 50,000/ul ) Anemia ( Hgb &lt; 10.0g/dl )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>